


Novartis Institutes for BioMedical Research

**Expedite Hit Discovery:  
Split & Pool in the 21st  
Century**

---

**Dr. Andreas Marzinzik**



Hit Finding

Single, Purified Libraries


ICLF

Fragment Based Screening

**Library synthesis for screening:**

- Diversity Oriented & Target Class
- New chemistry development

**Integrated Combinatorial Lead Finding (ICLF)  
One-Bead-One-Compound approach**




**Provide hits with modular structures amenable to rapid optimization by previously validated combinatorial chemistry**

**UHTS Plate:** > 2000 wells / plate


**Assay Volume:** 1-2  $\mu$ l

**Microtiter Plate:** 96 wells/ plate

**Assay Volume:** 200 $\mu$ l




Split-and-Mix: 27 products in **9** synthesis steps





One-bead-one-cpd

Parallel Synthesis, 27 products in **81** synthesis steps




**Requirements:** we need a well defined reaction compartment




⇒ Challenge: how do we analyse reactions on beads?

## Off-bead LC/MS/N


### Identity



### Purity




### Quantity





## On-bead IR

### Transmission





### ATR Reflectance















- **Medicinal chemistry aspects**  
physicochemical, potency, diversity, ADME/tox
- **Novelty**
- **Similarity to active compound classes**  
focus, complementarity
- **Modularity of the scaffold**  
BB availability, library size, feasibility...
- **Complexity of Chemistry**  
time of development, purity...





















# 1,3 Dipolar Cycladdition - Mechanism









*Hetero-Diels-Alder*





- NP have played a considerable part in the exploration and development of new drugs
- The hit-rate of pure natural compounds is higher than that of synthetic compounds
- Natural products provide unique chemical diversity, distinct from that found in the majority of synthetic libraries
- Biologically active natural products were evolutionarily selected and validated for binding to particular protein domains. Therefore such natural products are interesting starting points for library development







Epothilone B




total synthesis,  
semi-synthesis





Zearalenone derivative



semi-synthesis








⇒ Challenge: how do we identify active cpds from split-pool synthesis?

Split & pool  
synthesis:



Sizeable amounts / well

One bead / well

## Mixture

- Amount: as much as you want
- Screening of mixtures


- + save of screening cost
- no SAR, “mixtures problems”

## Single Compound

- Amount 1-30 nMol
- Deconvolution
- Screening with HT formats

- + no false positives, SAR possible
- redundancy, amount


## Activity profile



Circle diameters correspond to inhibition


● >80% inhibition


## MS analysis




Numbers correspond to  $M^+$

541	448	458	461	477
510	517	530	531	537









Analysis by F. Stoll, CADD

- **Proprietary compounds**
- **Complex chemical structures**
- **High diversity**
- **High quality**
- **Better success-rate than “single” compounds from CC**
- **Fast follow-up**
- **Which compound will give the next success story?**

## Chemistry/Technology

Fred Berst

Werner Breitenstein

Philipp Grosche

Markus Vögtle

Jürg Zimmermann

## Analytics

Rocco Falchetto

Erwin Hermes

Serge Moss

## Technical Support

Christoph Freslon

Raphael Gattlen

Faouria Nassur

Xavier Pelle

Stephanie Pickett

Erich Spieser